As MAP17 has been correlated with platinum-based compounds through ROS induction in other tumour types [10, 11], we evaluated sensitivity to cisplatin and carboplatin, the gold-standard therapy in most of the advanced lung cancer cases, in a panel of 13 adenocarcinoma cell lines (Additional file 1: Table S5). Here, PDZK1IP1 is linked to lung cancer.